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Inflammatory Markers in Bicuspid Transcatheter Aortic Valve Replacement 
Pantelic M.N., MS2, Nona P., MD, Wang D., MD. 
 
Background 
Aortic stenosis (AS) has a prevalence of 2%. Valve replacement is the definitive 
treatment for AS, with transcatheter aortic valve replacement (TAVR) offering a 
minimally invasive alternative to surgery. 
  
Bicuspid aortic valve (BAV) is the most common congenital cardiac abnormality. BAV 
patients are predisposed to AS, and comprise a distinct, younger TAVR patient 
population. Given limited prior work on inflammatory markers for TAVR risk 
assessment, this study sought to investigate if white blood cell count (WBC) correlates 
with BAV TAVR patient severity and post-TAVR outcomes. 
  
Methods 
A single-center retrospective analysis was performed on patients with BAV who 
underwent TAVR from 2014 to 2018 (N=37).  Patient demographics, symptomatic 
severity (NYHA class) and anatomic severity: aortic valve area (AVA) and indexed 
aortic valve area (AVAI) were collected. WBC prior to TAVR and post-TAVR 
complications/readmissions were also collected. Correlations between WBC, patient 
severity, and adverse outcomes were assessed using the Pearson and Spearman 
correlation tests, two-sample t-tests, and the Wilcoxon rank sum test. 
  
Results 
A statistically significant correlation (p = .041) was found between elevated 
pre-procedure WBC and patient NYHA class. No association was found between 
pre-procedure WBC and AVA (p = .723), AVAI (p = .961), or adverse 
outcomes/readmission post-procedure (p = .116). 
  
Conclusions 
A statistically significant correlation between pre-procedure WBC and NYHA class 
demonstrates that WBC is an accurate predictor of BAV patient’s functional symptom 
severity and could thus serve as a readily-accessible metric to stratify BAV TAVR 
patients in pre-procedure planning.  No correlation existed between WBC and anatomic 
valve severity. 
